ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - cabazitaxel, quantity: 50 mg - injection, concentrated - excipient ingredients: polysorbate 80; ethanol absolute; macrogol 300; citric acid - cabazitaxel ever pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - cabazitaxel, quantity: 45 mg - injection, concentrated - excipient ingredients: polysorbate 80; ethanol absolute; macrogol 300; citric acid - cabazitaxel ever pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

silver pharma s.l. - mercaptopurine - tablet - 50 milligram(s) - mercaptopurine

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - fulvestrant, quantity: 50 mg/ml - injection, solution - excipient ingredients: benzyl alcohol; benzyl benzoate; castor oil; ethanol - fulvestrant ever pharma is indicated for the treatment of postmenopausal women with: ? hormone-receptor (hr) positive, human epidermal growth factor receptor 2(her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy. ? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.

माल्टा - अंग्रेज़ी - Malta Medicines Authority

dali pharma gmbh brehmstrasse 56, 40239, dusseldorf,, germany - ceftazidime pentahydrate - powder for solution for injection/infusion - ceftazidime pentahydrate 2 g - antibacterials for systemic use

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - pituitary and hypothalamic hormones and analogues - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),

माल्टा - अंग्रेज़ी - Malta Medicines Authority

venus pharma gmbh am bahnhof 1-3, werne, d 59368, germany - powder for solution for injection/infusion - ceftriaxone 1 g - antibacterials for systemic use

माल्टा - अंग्रेज़ी - Malta Medicines Authority

venus pharma gmbh am bahnhof 1-3, werne, d 59368, germany - powder for solution for injection/infusion - ceftriaxone 2 g - antibacterials for systemic use

इसराइल - अंग्रेज़ी - Ministry of Health

ofek pharma ltd, israel - posaconazole - tablets delayed release - posaconazole 100 mg - posaconazole - treatment of the following fungal infections in adults:- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b.- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patient intolerant to itraconazole.- coccidioidomycosis in patients with disease refractory to amphotericin b, itraconazole or fludonazole or in patient intolerant to these medicinal products.- zygomycosis in patients intolerant of or with disease that is refractory to alternative therapy.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.these are also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplatic syndrome (mds) expected to result in prolonged neutropenia who are at high-risk of developing invasive fungal infections.-hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high-risk of developing invasive fungal infections.

माल्टा - अंग्रेज़ी - Malta Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - orodispersible tablet - olanzapine 5 mg - psycholeptics